Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q96AP4
UPID:
ZUP1_HUMAN
Alternative names:
Lys-63-specific deubiquitinase ZUFSP; Zinc finger with UFM1-specific peptidase domain protein
Alternative UPACC:
Q96AP4; Q5TD92; Q6PJH7; Q96NV6
Background:
Zinc finger-containing ubiquitin peptidase 1 (ZUFSP), also known as Lys-63-specific deubiquitinase, plays a pivotal role in maintaining genome stability by specifically cleaving 'Lys-63'-linked polyubiquitin chains. Its activity is crucial in preventing spontaneous DNA damage and promoting cellular survival under exogenous DNA stress, by modulating the ubiquitination status of replication protein A complex proteins.
Therapeutic significance:
Understanding the role of Zinc finger-containing ubiquitin peptidase 1 could open doors to potential therapeutic strategies.